A Microbicide is any substance or process that kills germs (bacteria, viruses, and other microorganisms that can cause infection and disease). Also called germicide.
A woman who is eight-months pregnant is the first participant to be enrolled into a study evaluating the safety and acceptability of two different HIV prevention approaches when used during pregnancy -- the monthly dapivirine vaginal ring, which is currently under regulatory review, and a daily antiretroviral (ARV) pill called Truvada, an approach already approved in several countries and commonly referred to as PrEP, short for pre-exposure prophylaxis.
The first clinical trial specifically designed to test the safety of the monthly dapivirine vaginal ring in pregnant women has begun in southern and eastern Africa.
In an open-label study of women in southern and eastern Africa, a vaginal ring that is inserted once a month and slowly releases an antiviral drug was estimated to reduce the risk of HIV by 39%, according to statistical modeling.
A vaginal microbicide that could prevent sexual transmission of HIV-1 in women has tremendous potential for saving lives and helping staunch an epidemic.
A clinical trial has begun to examine the safety and use of two HIV prevention tools--oral pre-exposure prophylaxis and a vaginal ring--in adolescent girls and young women in southern Africa.
AIDS is already the leading cause of death among girls and young women in much of Africa, and matters could only get worse, given that for every day that passes, 1,000 more girls ages 15 to 24 are likely to become infected with HIV.
University at Buffalo researchers received an $880,000 grant to help quicken the development of generic equivalents of contraceptives and other drugs delivered vaginally or to the uterus, such as by intrauterine devices
The bite from a brown recluse spider (Loxosceles) can cause skin necrosis, renal failure, and even death. A new ointment is being tested in Brazil, however. Its effects have already been proven in tests conducted in cell cultures and animal models.
As incredible as it sounds, a rice paddy field could one day yield an inexpensive way to prevent HIV.
The nonprofit International Partnership for Microbicides announced today the start of the first clinical trial of vaginal rings designed to slowly release the antiretroviral drug dapivirine over three months to prevent HIV in women.
Scientists at the Gladstone Institutes discovered that the vaginal immune system is suppressed in response to RNA viruses, such as Zika.
Most women who used an experimental vaginal ring for HIV prevention report that the physical act of sex was largely unaffected by using the product, which is inserted monthly for continuous wear.
Women who took part in ASPIRE, a trial that found a vaginal ring containing an antiretroviral (ARV) drug called dapivirine was safe and helped protect against HIV, will soon be offered the opportunity to use the ring as part of a new study called HOPE.
In an important scientific achievement for women's health, two large Phase III clinical trials -- The Ring Study and ASPIRE -- have shown that a monthly vaginal ring containing the antiretroviral drug (ARV) dapivirine can safely help prevent HIV-1 infection in women.
Enemas are commonly used by men who have sex with men (MSM) and transwomen (TW) before sexual intercourse. But these groups are vulnerable to HIV and a host of other sexually transmitted infections because enemas -- even those that use tap water -- can seriously damage the thin tissue lining the rectum, allowing for easier transmission of harmful viruses and bacteria.
CONRAD is pleased to announce a new funding agreement, in collaboration with the U.S. President's Emergency Plan for AIDS Relief and the U.S. Agency for International Development, in support of a human centered design (HCD) strategy to increase demand, use and adherence of HIV prevention products for high risk women in Africa.
An unprecedented potential "molecular tweezer" called CLR01, reported in the journal eLife, not only blocks HIV and other sexually transmitted viruses, but also breaks up proteins in semen that boost infection.
In a first for HIV prevention, an international team of researchers have completed follow-up of participants enrolled in a pivotal Phase III trial that tested the safety and effectiveness of a vaginal ring for preventing HIV in women.
Dr. Deborah Anderson from Boston University School of Medicine (BUSM) and her colleagues are challenging dogma about the transmission of the human immunodeficiency virus type 1 (HIV-1).
The Population Council will present new research on novel approaches to HIV, sexually transmitted infections (STIs), and unintended pregnancy prevention at the HIV Research for Prevention Conference, (HIV R4P) in Cape Town, South Africa. HIV R4P, which runs 28–31 October, is the first global scientific meeting dedicated exclusively to research on biomedical HIV prevention.